Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The evaluation and treatment of graves ophthalmopathy.

Literature DB >> 22443978

The evaluation and treatment of graves ophthalmopathy.

Marius N Stan¹, James A Garrity, Rebecca S Bahn.

Abstract

Optimum care of the patient with Graves ophthalmopathy (GO) is achieved through teamwork between the endocrinologist and ophthalmologist, with input from ancillary specialists as needed. Clinical evaluation should include determination of both the severity and the activity of the disease. It is important to assess early in the evaluation the impact of the disease on the patient's quality of life and their priorities and expectations regarding management. Once this information has been gathered, careful discussion between patient and physicians can define the management plan. This article reviews the pathophysiology, epidemiology, evaluation, and management of GO. Copyright Â

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 2012 PMID： 22443978 PMCID： PMC3898790 DOI： 10.1016/j.mcna.2012.01.014

Source DB: PubMed Journal: Med Clin North Am ISSN： 0025-7125 Impact factor: 5.456

94 in total

1. Low- versus high-dose radiotherapy for Graves' ophthalmopathy: a randomized, single blind trial.

Authors: G J Kahaly; H P Rösler; S Pitz; G Hommel
Journal: J Clin Endocrinol Metab Date: 2000-01 Impact factor: 5.958

2. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists.

Authors: Rebecca S Bahn Chair; Henry B Burch; David S Cooper; Jeffrey R Garber; M Carol Greenlee; Irwin Klein; Peter Laurberg; I Ross McDougall; Victor M Montori; Scott A Rivkees; Douglas S Ross; Julie Ann Sosa; Marius N Stan
Journal: Thyroid Date: 2011-04-21 Impact factor: 6.568

3. Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy.

Authors: M P Mourits; M F Prummel; W M Wiersinga; L Koornneef
Journal: Clin Endocrinol (Oxf) Date: 1997-07 Impact factor: 3.478

4. High-dose intravenous corticosteroid therapy for Graves' ophthalmopathy.

Authors: P E Macchia; M Bagattini; G Lupoli; M Vitale; G Vitale; G Fenzi
Journal: J Endocrinol Invest Date: 2001-03 Impact factor: 4.256

5. Effect of abnormal thyroid function on the severity of Graves' ophthalmopathy.

Authors: M F Prummel; W M Wiersinga; M P Mourits; L Koornneef; A Berghout; R van der Gaag
Journal: Arch Intern Med Date: 1990-05

6. Octreotide (long-acting release formulation) treatment in patients with graves' orbitopathy: clinical results of a four-month, randomized, placebo-controlled, double-blind study.

Authors: J L Wémeau; P Caron; A Beckers; V Rohmer; J Orgiazzi; F Borson-Chazot; M Nocaudie; P Perimenis; S Bisot-Locard; I Bourdeix; S Dejager
Journal: J Clin Endocrinol Metab Date: 2004-11-23 Impact factor: 5.958

7. Treatment of upper eyelid retraction associated with thyroid eye disease with subconjunctival botulinum toxin injection.

Authors: Jimmy M Uddin; Peter D Davies
Journal: Ophthalmology Date: 2002-06 Impact factor: 12.079

8. Long-term safety of orbital radiotherapy for Graves' ophthalmopathy.

Authors: Claudio Marcocci; Luigi Bartalena; Roberto Rocchi; Michele Marinò; Francesca Menconi; Eugenia Morabito; Barbara Mazzi; Salvatore Mazzeo; Maria Sole Sartini; Marco Nardi; Francesco Cartei; Luca Cionini; Aldo Pinchera
Journal: J Clin Endocrinol Metab Date: 2003-08 Impact factor: 5.958

Review 9. The CD40, CTLA-4, thyroglobulin, TSH receptor, and PTPN22 gene quintet and its contribution to thyroid autoimmunity: back to the future.

Authors: Eric M Jacobson; Yaron Tomer
Journal: J Autoimmun Date: 2007-03-21 Impact factor: 7.094

10. A stimulatory TSH receptor antibody enhances adipogenesis via phosphoinositide 3-kinase activation in orbital preadipocytes from patients with Graves' ophthalmopathy.

Authors: Seema Kumar; Sarah Nadeem; Marius N Stan; Michael Coenen; Rebecca S Bahn
Journal: J Mol Endocrinol Date: 2011-04-12 Impact factor: 5.098

28 in total

1. Computer-Assisted Three-Dimensional Planning for Orbital Decompression.

Authors: Nicholas Mahoney; Michael P Grant; Srinivas Murthy Susarla; Shannath Merbs
Journal: Craniomaxillofac Trauma Reconstr Date: 2014-11-14

Review 2. Current concepts in the molecular pathogenesis of thyroid-associated ophthalmopathy.

Authors: Yao Wang; Terry J Smith
Journal: Invest Ophthalmol Vis Sci Date: 2014-03-20 Impact factor: 4.799

3. Relationship between serum cholesterol and Graves' orbitopathy (GO): a confirmatory study.

Authors: G Lanzolla; E Sabini; M A Profilo; B Mazzi; A Sframeli; R Rocchi; F Menconi; M Leo; M Nardi; P Vitti; C Marcocci; M Marinò
Journal: J Endocrinol Invest Date: 2018-06-19 Impact factor: 4.256

4. Orbital decompression surgery and horse chestnut seed extract improved superior orbital vein blood flow in patients with thyroid-associated ophthalmopathy.

Authors: Yu-Jie Wu; Xin Wei; Man-Yi Xiao; Wei Xiong
Journal: Int J Ophthalmol Date: 2016-06-18 Impact factor: 1.779

5. The peripheral blood compartment in patients with Graves' disease: activated T lymphocytes and increased transitional and pre-naive mature B lymphocytes.

Authors: K Van der Weerd; P M Van Hagen; B Schrijver; D J Kwekkeboom; W W De Herder; M R J Ten Broek; P T E Postema; J J M Van Dongen; F J T Staal; W A Dik
Journal: Clin Exp Immunol Date: 2013-11 Impact factor: 4.330

Review 6. Current and Emerging Treatment Strategies for Graves' Orbitopathy.

Authors: Natalia Genere; Marius N Stan
Journal: Drugs Date: 2019-02 Impact factor: 9.546

Review 7. Ocular myositis.

Authors: Clare L Fraser; Simon E Skalicky; Avinash Gurbaxani; Peter McCluskey
Journal: Curr Allergy Asthma Rep Date: 2013-06 Impact factor: 4.806